ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1851

Antibody Against Ribonuclease-H Is a Novel Autoantibody Specifically Recognized in Systemic Lupus Erhythematosus

Kazuhisa Nozawa1, Kentaro Doe2, Kaori Hiruma3, Yusuke Yamada4 and Yoshinari Takasaki5, 12-1-1 Hongo Bunkyo-ku, Juntendo University, Tokyo, Japan, 22-1-1 Hongo, Bunkyo-Ku, Juntendo University School of Medicine, Tokyo, Japan, 3Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 4Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 5Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: autoantibodies, autoantigens, central nervous system involvement and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Proliferating cell nuclear antigen (PCNA) is known to be an autoantigen specifically recognized in patients with SLE. PCNA constitutes PCNA-complex along with several PCNA-binding proteins in vivo. We have consecutively published that autoantibodies to PCNA-binding proteins are easily produced in SLE patients as well as autoantibody to PCNA itself. Furthermore, we have recently published the novel serum autoantibody to chromatine assembly factor-1(CAF-1), which belongs to the PCNA-binding proteins, might be an useful biomarker for neuropsychiatric (NP) SLE. Ribonuclease-H (RNase-H) also belongs to the PCNA-binding proteins and functions as a regulating factor for cell division in coordination with other PCNA-binding proteins such as CAF-1. Therefore, we assume that RNase-H will be a candidate of autoantigen specifically recognized in SLE and investigated the clinical association of anti-RNase-H antibody with SLE patients.

Methods:

Patients sera consisting of SLE (n=57), PM/DM (n=40), SSc (n=39), SS (n=28), MCTD (n=28), RA (n=29), and normal healthy controls (NHCs) (n=73) were collected from serum bank of Juntendo University Hospital with their informed consent. Immunoreactivity against both RNase-H and CAF-1 recombinant antigens was evaluated by ELISA and was further confirmed by immunoblotting. The cut-off value designating a positive reaction in ELISA was defined as the mean value of NHCs +3 standard deviations.

Results:

Serum anti-RNase-H antibody was observed in 33% of SLE patients. The anti-RNase-H antibody was not recognized in both all control diseases and NHCs. Moreover, the coexistence of anti-RNase-H antibody and anti-U1 RNP antibody revealed high incidence of NPSLE. Moreover, titer of anti-RNase-H antibody was strongly correlated with titer of anti-CAF-1 antibody in regression analysis.

Conclusion:

In the present study, we identified anti-RNase-H antibody as a novel autoantibody specifically recognized in SLE. Measurement of anti-RNase-H antibody can be used for the diagnosis of SLE. Moreover, it might be a useful biomarker for NPSLE when anti-U1 RNP antibody coexists. The strong correlation in titer of anti-RNase-H and CAF-1 antibodies suggested that a breakdown of immune tolerance against component proteins of PCNA-complex lead to elicit autoimmune response to the other components of PCNA-binding proteins. This phenomenon is considered as epitope spreading which plays important role for the autoantibody production in SLE.


Disclosure: K. Nozawa, None; K. Doe, None; K. Hiruma, None; Y. Yamada, None; Y. Takasaki, None.

To cite this abstract in AMA style:

Nozawa K, Doe K, Hiruma K, Yamada Y, Takasaki Y. Antibody Against Ribonuclease-H Is a Novel Autoantibody Specifically Recognized in Systemic Lupus Erhythematosus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/antibody-against-ribonuclease-h-is-a-novel-autoantibody-specifically-recognized-in-systemic-lupus-erhythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibody-against-ribonuclease-h-is-a-novel-autoantibody-specifically-recognized-in-systemic-lupus-erhythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology